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Introduction {#sec1}
============

Breast cancer is the most common cancer in women after skin cancer. Even though cancer mortality has been decreased, breast cancer remains a fatal disease, with 266,120 estimated new cases in the United States and an estimated mortality rate of 40,920 (<https://seer.cancer.gov/statfacts/html/breast.html>). The primary cause of death by breast cancer is the dissemination of the cancer cells prior to disease diagnosis and treatment that results in tumor growth at secondary sites and metastases ([@bib12], [@bib48]).

Postpartum mammary cancer that includes breast cancers that develop within 10 years after child birth represents a distinct type of the disease that accounts for about 29% of all breast cancers for Caucasian women diagnosed ≤45 years ([@bib14], [@bib5]). Postpartum breast cancer has a poor prognosis ([@bib16], [@bib1], [@bib18], [@bib8]) compared with non-postpartum breast cancer or of that during pregnancy ([@bib18], [@bib46]) because of increased risk of metastasis. Even though pregnancy has a protective effect against breast cancer, this effect is exerted only many years after childbirth ([@bib17], [@bib21]). Contrarily, in a short period after pregnancy there is a transient risk for breast cancer that peaks between 5 and 10 years postpartum ([@bib14], [@bib38]). Even though breast cancer death rates overall are decreasing, postpartum breast cancer remains a principal cause of mortality especially for young women ([@bib14], [@bib5]).

Although the metastatic ability is inherent to the cancer cells, certain factors have been identified as potent activators of the process. One of these factors is mammary gland involution, a process in which the lactating gland returns to a morphologically nonsecretory pre-pregnant state and involves extensive tissue remodeling. Involution is characterized by the alveolar programmed cell death, mammary gland remodeling, and adipocyte repopulation ([@bib43], [@bib51]). The microenvironment of the involuting gland has been shown to be tumor promoting in different experimental mouse models ([@bib29], [@bib28], [@bib26], [@bib3]). Involution occurs in two phases. The first one is reversible, is characterized by epithelial cell death, and is macrophage dependent ([@bib24], [@bib32]). The second phase is non-reversible and is characterized by further cell death, accompanied by tissue-remodeling, collapsing of the lobuloalveolar structures, and adipocyte repopulation ([@bib24]).

The mechanisms through which the microenvironment of involution promotes tumor growth include activated fibroblasts ([@bib15]), increased fibrillar collagen, COX-2 (cyclooxygenase-2) overexpression from epithelial cells, abundant extracellular matrix (ECM) immune cell infiltration, and lymphangiogenesis ([@bib32], [@bib22], [@bib39], [@bib25], [@bib13], [@bib44], [@bib4], [@bib9]. Based on these findings therapeutic strategies have been proposed targeting either the immune cells such as immunotherapy ([@bib13]) or non-steroidal anti-inflammatory drugs (NSAIDs) ([@bib25], [@bib33]) for COX-2 inhibition and suppression of fibroblasts\' tumor promoting activity ([@bib15]).

The inflammatory microenvironment of involution is characterized by the upregulation of chemokines ([@bib2], [@bib42], [@bib36], [@bib7]). Our previous studies showed the involvement of the chemokine CCL8 in cancer and metastasis through modulation of the tumor-promoting activity of the tumor microenvironment. *Ccl8* is a member of a conserved chemokine cluster, known as CC cluster, located in the conserved MCP region of the chromosome 11C in mice and 17q12 in humans ([@bib30]). CCL8 is involved in the immune response by attracting monocytes, T lymphocytes, natural killer cells (NK), basophils, mast cells, and eosinophils ([@bib41], [@bib34], [@bib37]). According to our and others\' results cancer cells can stimulate CCL8 production in adjacent stromal fibroblasts in breast and colon cancers ([@bib11], [@bib10], [@bib45]). The prometastatic activity of CCL8 has been associated to the development of a CCL8 gradient between the neoplastic epithelium, the stroma, and the peripheral tissues and is correlated with poor prognosis in patients with breast cancer ([@bib11]). This significance of CCL8 in regulating the directional movement of other cell types such as the innate lymphoid cells in the lungs was also recently confirmed and extended, underscoring the role of CCL8 in orchestrating cell migration in different pathophysiological conditions ([@bib35]).

In view of the extensive mobilization of various chemokines during mammary gland involution, in the present study we explored the specific role of CCL8 in the development of postpartum breast cancer.

Results {#sec2}
=======

CCL8 Expression Is Increased in the Mammary Gland during Involution {#sec2.1}
-------------------------------------------------------------------

Publicly available microarray data show that Ccl8 is highly expressed during mammary gland involution, compared with the stages of puberty, pregnancy, and lactation ([@bib36]) ([Figure 1](#fig1){ref-type="fig"}A). We confirmed this observation by qPCR analysis of Ccl8 mRNA levels in mammary glands from nulliparous mice or mice at involution day 4. The expression of Ccl8 mRNA in mice during involution was induced 4-fold (p \< 0.05) compared with nulliparous mice ([Figure 1](#fig1){ref-type="fig"}B). In addition, mouse CCL8 protein levels measured by ELISA were 7-fold (p \< 0.05) increased at involution day 5 and 4-fold increased at involution day 7 (p \< 0.05) ([Figure 1](#fig1){ref-type="fig"}C).Figure 1CCL8 Expression at Different Stages of Mammary Gland Development(A) Microarray data using Affymetrix microarray (MG-U74v2) obtained from [@bib36] showing Ccl8 expression in mammary glands from C57B6 mice, puberty (6 weeks) (n = 3), pregnancy (14 days) (n = 2), lactation (10 days) (n = 2), and involution (4 days) (n = 2).(B) Ccl8 gene expression in mammary glands from nulliparous mice or mice at involution day 4 (n = 4). Results are shown as average fold expression compared with nulliparous mice +SEM.(C) CCL8 levels in mammary glands from wt mice at involution day 0 (lactation day 10) (n = 4), 2 (n = 2), 5 (n = 4), and 7 (n = 4). CCL8 levels were determined by ELISA. Results are shown as average +SEM (∗, p \< 0.05 Student\'s t test).

To determine whether CCL8 loss affected mammary gland remodeling induced by involution, we performed histological analysis in mammary glands from wild-type (wt) or Ccl8KO mice. The deletion of CCL8 did not impair pregnancy or lactation. The histological appearance of the mammary glands from wt and Ccl8KO mice was similar during mammary involution, following the cessation of lactation ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The absence of morphological differences between wt and Ccl8KO mice was confirmed by quantification of the epithelial surface area occupying the glands ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and by assessment of β-casein protein levels by western blot ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These results indicate that CCL8 does not affect the remodeling of the mammary gland tissue during involution.

CCL8 Induces the Recruitment of Macrophages and Neutrophils in the Mammary Glands {#sec2.2}
---------------------------------------------------------------------------------

Since CCL8 is involved in the inflammatory response ([@bib34]), we investigated the infiltration of macrophages and neutrophils in the mammary glands from wt or Ccl8KO mice. Immunohistochemistry for the macrophage marker F4/80 and the neutrophil marker NM indicated that CCL8 is instrumental in recruiting macrophages during involution. As shown in [Figure 2](#fig2){ref-type="fig"}, following lactation a transient increase in the number of macrophages was detected in the mammary glands from wild-type mice during involution that peaked at day 5 (p \< 0.05, p \< 0.001) ([Figures 2](#fig2){ref-type="fig"}A and 2B). This effect was alleviated following *Ccl8* ablation suggesting that this chemokine is crucial for the recruitment of F4/80-positive macrophages, during involution. Similar trends, albeit insignificant, were also revealed for neutrophils implying a wider role for CCL8 in immune cell recruitment beyond macrophages ([Figures 2](#fig2){ref-type="fig"}C and 2D).Figure 2Macrophage and Neutrophil Recruitment in the Mammary Glands from Ccl8KO Mice at Different Stages of Mammary Gland DevelopmentRepresentative images (40x) of mammary glands from wt or Ccl8KO mice at involution days 5 and 7 (n = 4) stained for F4/80 (A), neutrophil marker (NM) (C), Arginase I (E), and iNOS (G). Scale bar, 50 μm. Quantification of cells per optic field positive for F4/80 (B), NM (D), Arginase I (F), and iNOS (H) of the results described above. Results are shown as average + SEM (∗, p \< 0.05; ∗∗, p \< 0.001 Student\'s t test).

To dissect further the ability of CCL8 to attract tumor-promoting macrophages, we further determined the subtypes of M1 and M2 macrophages by staining for iNOS and arginase I, respectively, the mammary glands from wt and Ccl8KO mice at different days of involution. The results showed three times less M2 macrophages at involution day 7 in Ccl8KO mice compared with wt mice ([Figures 2](#fig2){ref-type="fig"}E and 2F), suggesting that CCL8 attracts primarily M2 macrophages, as opposed to the M1 macrophages, the number of which remained unaffected by the ablation of *Ccl8* ([Figures 2](#fig2){ref-type="fig"}G and 2H).

CCL8 Is Tumor Promoting during Involution {#sec2.3}
-----------------------------------------

Based on the observation that CCL8 is a chemoattractant for M2 macrophages, which are known to be tumor promoting, we wanted to determine whether *Ccl8* ablation could directly affect the development of postpartum breast cancer at either the level of initiation or the level of progression. To explore this hypothesis, we introduced the *Ccl8*-null allele into an immunodeficient background (SCID) and mice, either nulliparous or during involution, were implanted with MCF10.DCIS.com breast cancer cells ([@bib26]). For comparison, MCF10.DCIS.com cells were implanted in SCID littermates that had the *Ccl8* gene intact. MCF10.DCIS.com cells were selected for this experiment because they had been used successfully in the past to study involution-associated breast cancer ([@bib26]). Consistently with earlier findings, tumorigenesis showed a positive trend during involution ([Figure S2](#mmc1){ref-type="supplementary-material"}) ([@bib29], [@bib28], [@bib26], [@bib3]). In the nulliparous females, no differences were observed between wt and Ccl8KO mice in both tumor growth rates and the period required for the development of palpable tumors ([Figure 3](#fig3){ref-type="fig"}A, pairwise comparisons in tumor growth of individual mice are shown). However, when cancer cells were injected at the second day of involution, after 10 days of lactation, the latency for tumor onset was drastically delayed in the *Ccl8*-deficient animals (p \< 0.05) ([Figure 3](#fig3){ref-type="fig"}B). This finding suggests that CCL8 is tumor promoting only during involution but not in nulliparous animals. As soon as tumors were established their growth rate was not affected by CCL8, which in turn suggests that, although CCL8 is essential for tumor onset, it is not capable of affecting tumor progression, a notion that is also supported by the observation that histologically tumors in wt and Ccl8KO mice were indistinguishable ([Figure 3](#fig3){ref-type="fig"}D).Figure 3CCL8 Is Tumor Promoting during Involution(A) Growth of MCF10.DCIS.com (2x10^5^ cells) in SCID (wt) and Ccl8KOSCID (Ccl8KO) mice implanted in about 3-month nulliparous mice (n = 6). Results are shown as average +SEM.(B) Growth of MCF10.DCIS.com (2x10^5^ cells) in SCID (wt) and Ccl8KOSCID (Ccl8KO) mice implanted in day 2 of forced involution that followed 10 days of lactation (n = 6). The inset shows tumor onset in different groups. Results are shown as average + SEM (∗, p \< 0.05). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(C) Same as (B) with macrophage depletion (n = 5) starting from lactation day 7, using five daily intraperitoneal injections of 1 mg clodronate liposomes. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.(D) Hematoxylin and eosin (H&E) in tumors from wt or Ccl8KO nulliparous mice or mice implanted in involution (n = 6). Scale bar, 20 μm in 20x. N, nulliparous; PR, pregnancy; LAC, lactation; INV, involution.

The Tumor-Promoting Activity of CCL8 during Involution Involves M2 Macrophage Recruitment {#sec2.4}
-----------------------------------------------------------------------------------------

The observation that CCL8 is tumor promoting, combined with the reduced infiltration of M2 macrophages in Ccl8KO mice during involution, predicts that ablation of macrophages would affect primarily wt and only minimally Ccl8KO animals. To test this hypothesis, we pharmacologically depleted macrophages by administration of clondronate liposomes ([@bib47]) for 5 days, starting from lactation day 7 until involution day 2 and then injected cancer cells and monitored tumor onset and growth. The tumor-promoting effect of CCL8 during involution was abolished by macrophage depletion in the wt animals but did not affect Ccl8KO animals at which the tumor-promoting M2 macrophages were already diminished ([Figure 3](#fig3){ref-type="fig"}C). To rule out the possibility that clodronate influences tumorigenesis by impairing involution we administered clodronate liposomes in wt and Ccl8KO mice and monitored the efficacy of post-lactation mammary gland remodeling; however, no differences between the wt and Ccl8KO mice were noted ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

To further determine whether CCL8 increases M2 subtype macrophage infiltration during tumorigenesis, we injected MCF10.DCIS.com cells enclosed in Matrigel in the mammary glands from wt or Ccl8KO SCID mice at involution day 2 and then recorded the number of M2 macrophages that are recruited by the newly implanted tumor in relation to the *Ccl8* status of the mammary glands. To that end, following 2 days of inoculation, cancer cell-containing Matrigel nodules implanted in wt and Ccl8KO mice were dissected and stained for the M2 marker arginase I. IHC indicated the decreased number of M2 subtype macrophages in the Matrigel nodules from Ccl8KO mice (p \< 0.05) ([Figures 4](#fig4){ref-type="fig"}A and 4B). This finding is consistent with the specific ability of CCL8 to promote tumor growth by recruiting M2 macrophages ([Figures 2](#fig2){ref-type="fig"}E and 2F).Figure 4CCL8 Promotes Tumor Growth by Recruiting M2 Macrophages(A) Representative images (20x) of mammary glands stained for Arginase I from SCID (wt) and Ccl8KOSCID (Ccl8KO) mice implanted with MCF10.DCIS.com (1x10^6^ cells) enclosed in Matrigel at day 2 of forced involution that followed 10 days of lactation (n = 5). Animals were sacrificed 2 days later. Scale bar, 10 μm.(B) Quantification of cells per optic field positive for Arginase I of the results described above. Results are shown as average + SEM (∗, p \< 0.05, Student\'s t test).

Discussion {#sec3}
==========

Postpartum breast cancer represents one of the most aggressive forms of breast cancer, but despite the progress, the options for specific therapeutic intervention against the disease are truly limited. In an attempt to explore specific therapeutic options for postpartum breast cancer management we investigated if modulation of CCL8 activity is linked to involution-associated promotion of tumor growth. Our results revealed an essential role for CCL8 in the promotion of involution-associated breast cancer that mechanistically was linked to the recruitment of the tumor-promoting M2 macrophages. Macrophages are recruited to the mammary gland at the second phase of involution ([@bib28], [@bib31]), and this effect, according to our present data, is mediated by CCL8 that is highly expressed during mammary gland involution. Noteworthy, the expression profile of CCL8 differed from that of CCL2 that is structurally related to CCL8 and encoded by a gene located in the same chemokine cluster with CCL8 ([@bib30]). CCL2 protein levels had a peak at day 2 of involution followed by a decrease ([@bib31], [@bib27]), contrary to the protein levels of CCL8 that peaked at day 5 and maintained high until day 7. These findings imply that CCL8 might have different functions and apparently different regulation during involution compared with other chemokines that are members of the same cluster ([@bib30]). This is also suggested by the fact that despite *Ccl8* ablation reduced macrophage numbers in the mammary gland during involution, tissue remodeling was not delayed during involution. Direct activities of CCL8 onto the mammary epithelial cells, in combination with its delayed expression profile as compared with other chemoattractive cytokines of the same cluster, may offset the anticipated delay in involution due to macrophage depletion.

Furthermore, CCL8 causes increased infiltration of M2 subtype macrophages specifically at involution day 7. Consistent with this result is the high expression of the receptors CCR1 and CCR5 in M2 macrophages compared with M1 ([@bib50]) that are receptors for CCL8 ([@bib34], [@bib40], [@bib37]).

In the context of involution-associated tumorigenesis, ablation of *Ccl8* significantly delayed the onset of breast tumors during involution, whereas in nulliparous mice it had no effect. This finding suggests that in the absence of CCL8 tumor growth is considerably impeded, rendering CCL8 as a major determinant of the tumor-promoting activity of involution. The fact that histology or tumor growth rates did not differ in tumors from wt and Ccl8KO mice indicates that CCL8 affects tumor initiation by developing a proinflammatory microenvironment but not the morphogenesis of tumors or their development beyond onset. To further support this notion, *in vivo* depletion of macrophages abolished the tumor-promoting effect of CCL8 during involution, only in wt animals. A limitation of this strategy for macrophage depletion is that clodronate was shown capable of depleting additional immune cells in peripheral tissues such as dendritic cells ([@bib49], [@bib20], [@bib19], [@bib23]), which may also contribute directly or indirectly to the remodeling of the mammary gland during involution. Nevertheless, despite this limitation, in animals with disrupted macrophage function, tumor onset was similar in the wt and the *Ccl8*-deficient groups suggesting that the tumor-promoting action of CCL8 in involution is strictly dependent on the presence of macrophages. Consistently with this notion, CCL8 was recently identified as a part of the breast tumor associated macrophages (TAM) signature in humans ([@bib6]). Macrophages play a crucial role in the normal postpartum mammary gland involution ([@bib32]), and specifically the M2 subtype of macrophages promotes the development of a proinflammatory and protumorigenic microenvironment during involution ([@bib31]). In our experimental model, CCL8 facilitates the infiltration of M2 macrophages in the presence of cancer cells during involution and accelerates tumor onset.

Our previously published results ([@bib11]) show that stromal cells and especially fibroblasts constitute a primary source of CCL8 and that breast cancer cells activate CCL8 expression in fibroblasts. Consistent with these results, recent studies show that activated mammary fibroblasts within the involuting mammary gland have protumorigenic function that can be suppressed by NSAIDs ([@bib15]).

Collectively our data show that CCL8 is instrumental for the pathogenesis of postpartum breast cancers by attracting tumor-promoting macrophages during involution. These results, combined also with the finding that inhibition of CCL8 does not affect physiological mammary function, suggest the potential value of CCL8 as a target molecule for the management of postpartum breast cancers.

Limitations of the Study {#sec3.1}
------------------------

In the present study, we used a mouse model of immunodeficient transgenic animals for the tumor growth studies. The findings need to be replicated in a syngeneic model to include the immune responses of the hosts. For *in vivo* macrophage depletion we used clodronate liposomes. However, clodronate was found to deplete additional immune cells such as dendritic cells in the skin and kidney. Evaluation of the effect of clodronate on immune cells other than macrophages in the mammary gland and the physiological implications may be considered.
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Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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